65,437 trials
HIV/AIDS · Mobile Health · Young Adults
Primary: Feasibility: Rate of Participant Retention — 22 Participants
Halitosis
Primary: Adjusted Mean Change From Baseline (Day 0, Pre-Brushing) to Week 3 (Pre-Brushing) in Breath Organoleptic Scores — -1.23; 0.07 Score on a scale — p=<0.0001
All Malignancies · Advanced Malignancies · Hematologic Malignancy
Primary: Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to 12 Hours of Quantifiable Concentration (AUC0-12h) of Tazemetostat — 2180; 1830…
Alzheimer Disease
Primary: Total Number of Individuals With Successful Opening of the BBB — 5 Participants
Arthritis · Diabetes · Depression
Primary: Changes in Depression as Measured by the Patient Health Questionnaire (PHQ-9) — 8.65; 7.82; 7.18; 7.41 units on a scale — p=<0.001
Overweight · Obese · Healthy
Primary: Visits to Restaurants — 3.1; 2.6; 2.9; 2.6 Number of FFR Visits
Kidney Failure · Kidney Diseases
Primary: Thigh Cross Sectional Area — 58.2 centimeters squared
Critical Illness
Primary: Glycemic Penalty Index (GPI) During the Intervention — 9.8; 12.4 units on a scale — p=<0.0001
COVID-19 Pneumonia · COVID-19 Respiratory Infection · Acute Respiratory Failure
Primary: Survival — 9; 5 Participants
Nicotine Dependence
Primary: Drug Effect Questionnaire - Stimulatory Effects — 39.37; 33.48; 32.35; 33.23 units on a scale — p=0.93
Pitt Hopkins Syndrome
Primary: Daily Stool Record (DSR( — -2.3; 0 days
Lower Back Pain · Lumbar Radiculopathy
Primary: Pain Score During Procedure — 3.7; 3.2; 5.2 score on a scale
Hepatitis B, Chronic
Primary: Incidence of Treatment-emergent Adverse Events (TEAEs) — 1; 2; 0; 2 Participants
Testicular Cancer
Primary: Number of Participants With 2-year Event-Free Survival (EFS) — 28; 11 Participants
Autism Spectrum Disorder
Primary: Developmental Neuropsychological Assessment (NEPSY) Memory for Faces Delayed